Any current/future new fundraising through debt or equity?

There is no mention of any current or planned new fundraising through debt or equity. The company has already paid off its entire debt book, resulting in a significant decline in finance costs. The company currently has Rs.64 crores of unutilized IPO proceeds available, intended for CAPEX over time. Management highlighted no plans for increased spending beyond controlled levels (e.g., ad spends less than 5%), and they seem focused on organic growth and operational efficiencies. No discussions about fresh equity or debt issuance were referenced during the call.

Any current/future capex/capital investment/strategic investment?

The company has Rs.64 crores of unutilized IPO funds earmarked for deployment in CAPEX over time. In H1 FY26, Laxmi Dental has already incurred CAPEX of around Rs.6 crores. There is ongoing investment in R&D, particularly for regulatory clearances to expand the product profile to 150 countries. The company is focusing on backward integration in aligner and pediatric product businesses and may consider it for scanners or other materials to create more value. No major additional R&D expenses planned; current R&D spend is controlled. Overall, capital investments are directed towards geographic ex

Future growth expectations in sales/revenue/volumes?

Revenue growth guidance for FY26 is targeted at 20%-25%, with confidence in achieving this range despite global uncertainties. Scanner sales are expected to continue strongly through FY26 and into FY27, contributing to sustained growth. International lab business is expanding with new customers and geographies, supporting faster growth than domestic markets (39.2% YoY for Q2). Domestic lab business anticipated to grow rapidly due to increased scanner adoption among the dental network (23.2% growth in Q2 FY26). The aligner segment aims to regain its historic 25%-30% growth post regulato

Future growth expectations in earnings/operating earnings/profits/EPS?

Laxmi Dental targets a 20%-25% revenue growth for FY26, maintaining strong top-line momentum. PAT margins are guided between 13%-15% for FY26, inclusive of current tariff impacts, with potential improvement as tariffs ease. EBITDA margin target is set at 20% in the mid-to-long term beyond FY26, indicating margin expansion ambitions. Scanner sales, while strategic, currently compress margins but are expected to stabilize and contribute to margin recovery by FY27. The management expects H2 margins to be stronger than H1, with operating efficiency improving through geographic and customer

Laxmi Dental LtdQ2 FY26Healthcare Equipment & Supplies

Laxmi Dental Ltd Q2 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹185P/E: 29.2Market Cap: ₹1.0K CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Revenue growth guidance for FY26 is targeted at 20%-25%, with confidence in achieving this range despite global uncertainties.
Scanner sales are expected to continue strongly through FY26 and into FY27, contributing to sustained growth.
International lab business is expanding with new customers and geographies, supporting faster growth than domestic markets (39.2% YoY for Q2).
Domestic lab business anticipated to grow rapidly due to increased scanner adoption among the dental network (23.2% growth in Q2 FY26).
The aligner segment aims to regain its historic 25%-30% growth post regulatory clearances such as CE expected by Q4 FY26.
Expansion strategies include increasing penetration among various dentist types (orthodontists, general, pediatric).
Long-term growth driven by investments in digital dentistry, AI integration, brand visibility, and geographically broad market access (~150 countries targeted).
Emphasis on sustainable margin growth alongside top-line growth without excessive spending.

Margin guidance

Category 3

Laxmi Dental targets a 20%-25% revenue growth for FY26, maintaining strong top-line momentum.
PAT margins are guided between 13%-15% for FY26, inclusive of current tariff impacts, with potential improvement as tariffs ease.
EBITDA margin target is set at 20% in the mid-to-long term beyond FY26, indicating margin expansion ambitions.
Scanner sales, while strategic, currently compress margins but are expected to stabilize and contribute to margin recovery by FY27.
The management expects H2 margins to be stronger than H1, with operating efficiency improving through geographic and customer base expansion.
Long-term growth is supported by investments in digital dentistry, AI integration, and expanding product portfolios (Aligners, Pediatric segment).
The company foresees improved profitability with resolution of US tariff uncertainties and scaling of subscription/software models post technology adoption.
Overall, earnings growth and margin expansion are key priorities, with gradual realization over the medium to long term.

See what Laxmi Dental Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or planned new fundraising through debt or equity.
The company has already paid off its entire debt book, resulting in a significant decline in finance costs.
The company currently has Rs.64 crores of unutilized IPO proceeds available, intended for CAPEX over time.
Management highlighted no plans for increased spending beyond controlled levels (e.g., ad spends less than 5%), and they seem focused on organic growth and operational efficiencies.
No discussions about fresh equity or debt issuance were referenced during the call.

Order book

The transcript excerpts do not explicitly provide specific figures or details regarding the current or expected order book or pending orders for Laxmi Dental Limited. However, the following points can be inferred: - Laxmi Dental is experiencing growth with a 23% increase in their dental lab business, indicating healthy ongoing demand. - Scanner sales are strong and contributing to future scale, suggesting a growing order pipeline from digital dentistry adoption. - Expansion into new geographies and increasing dentist network breadth indicates a potential rise in order volumes. - Ongoing regulatory clearances (e.g., Kids-E Dental CE mark expected in Q4) point toward upcoming opportunities and increased orders. - The company mentions continuous quarter-on-quarter growth across segments and expects stronger second halves historically. No explicit numeric order backlog or pending order data is provided in the transcript.

See what Laxmi Dental Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has Rs.64 crores of unutilized IPO funds earmarked for deployment in CAPEX over time.
In H1 FY26, Laxmi Dental has already incurred CAPEX of around Rs.6 crores.
There is ongoing investment in R&D, particularly for regulatory clearances to expand the product profile to 150 countries.
The company is focusing on backward integration in aligner and pediatric product businesses and may consider it for scanners or other materials to create more value.
No major additional R&D expenses planned; current R&D spend is controlled.
Overall, capital investments are directed towards geographic expansion, product portfolio enhancement, and scaling digital dentistry technologies such as scanners.

Track Laxmi Dental Ltd — get its next earnings analysis in your feed

How does Laxmi Dental Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature

ThisLaxmi Dental Ltd

Rev 2Mar 3

See where Laxmi Dental Ltd sits in Healthcare Equipment & SuppliesSee which companies these are, and every other name in the sector.Open rankings

How does Laxmi Dental Ltd rank in Healthcare Equipment & Supplies?

Compare Laxmi Dental Ltd against every Healthcare Equipment & Supplies company (Q2 FY26) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

What Laxmi Dental Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

QMS Medical Allied Services Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹37.3 crore . Key investor presentation takeaways from QMS Medical Allied Services Ltd's Q3 FY26 investor presentation — and how
Avience Biomedicals Ltd (Q1 FY27)
New manufacturing facility has capacity to support peak revenue of around ₹250–265 crore, subject to product mix and approvals. Key concall takeaways from…
Fischer Medical Ventures Ltd (Q2 FY25)
EBITDA: ₹36.3 crore, a 45.5% year-on-year increase. Key concall takeaways from Fischer Medical Ventures Ltd's Q2 FY25 earnings call — and how it ranks against…
Fischer Medical Ventures Ltd (Q1 FY27)
The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year…

Compare:vs Molbio Diagnosti vs Fischer Medical Ventures Ltd vs Tarsons Products Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →